Trial reportThe Journal of clinical investigation2021
Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia.
Trial report in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03906253 (Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Hydroxytyrosol Improves UV-Induced Skin Photoaging via PI3K-AKT/MAPK/JAK-STAT and NF-κB Pathways: Insights From Keratinocytes and In Vivo Validation.Phytotherapy research : PTR · 2026Article
- Chemoprevention in Skin Cancer: What Advice?Cancers · 2026Review
- Five-year follow-up on randomized controlled trial of fractionated laser resurfacing as prophylaxis against actinic neoplasia.Journal of the American Academy of Dermatology · 2026Article
- Translesion Synthesis DNA Polymerase Gene Expression Is Impacted by Age and IGF-1 in Epidermal Human Skin.JID innovations : skin science from molecules to population health · 2025Article
- Can the Pursuit of an Ageless Face Redefine Medicine? Exploring Dermatology's Role in the Quest for Immortality.The Journal of clinical and aesthetic dermatology · 2025Review
- Photocarcinogenesis of the skin: Current status and future trends.The Kaohsiung journal of medical sciences · 2025Review
- Recent advances in dermal fibroblast senescence and skin aging: unraveling mechanisms and pioneering therapeutic strategies.Frontiers in pharmacology · 2025Review
- Drug Delivery System Targeting Cancer-Associated Fibroblast for Improving Immunotherapy.International journal of nanomedicine · 2025Review
- Epigenetic Modifications and the Role of Medical Lasers in Enhancing Skin Regeneration.Journal of cosmetic dermatology · 2025Article
- Fibronectin Promotes Wound Healing in an Atopic Human Skin Xenografting Model.The Journal of investigative dermatology · 2024Article
- Ablative fractional laser treatment reduces hedgehog pathway gene expression in murine basal cell carcinomas.Lasers in medical science · 2024Article
- Review
- Epidermal mutation accumulation in photodamaged skin is associated with skin cancer burden and can be targeted through ablative therapy.Science advances · 2023Article
- Repeated exposure to fractional COLasers in surgery and medicine · 2023Article
- Article
- Wounding Therapies for Prevention of Photocarcinogenesis.Frontiers in oncology · 2021Review
- Downregulated miR-181a alleviates HAnais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUNDThe loss of insulin-like growth factor 1 (IGF-1) expression in senescent dermal fibroblasts during aging is associated with an increased risk of nonmelanoma skin cancer (NMSC). We tested how IGF-1 signaling can influence photocarcinogenesis during chronic UVB exposure to determine if fractionated laser resurfacing (FLR) of aged skin, which upregulates dermal IGF-1 levels, can prevent the occurrence of actinic keratosis (AK) and NMSC.METHODSA human skin/immunodeficient mouse xenografting model was used to test the effects of a small molecule inhibitor of the IGF-1 receptor on chronic UVB radiation. Subsequently, the durability of FLR treatment was tested on a cohort of human participants aged 65 years and older. Finally, 48 individuals aged 60 years and older with considerable actinic damage were enrolled in a prospective randomized clinical trial in which they underwent a single unilateral FLR treatment of one lower arm. Numbers of AKs/NMSCs were recorded on both extremities for up to 36 months in blinded fashion.RESULTSXenografting studies revealed that chronic UVB treatment with a topical IGF-1R inhibitor resulted in a procarcinogenic response. A single FLR treatment was durable in restoring appropriate UVB response in geriatric skin for at least 2 years. FLR resulted in sustained reduction in numbers of AKs and decreased numbers of NMSCs in the treated arm (2 NMSCs) versus the untreated arm (24 NMSCs).CONCLUSIONThe elimination of senescent fibroblasts via FLR reduced the procarcinogenic UVB response of aged skin. Thus, wounding therapies are a potentially effective prophylaxis for managing high-risk populations.TRIAL REGISTRATIONClinicalTrials.gov (NCT03906253).FUNDINGNational Institutes of Health, Veterans Administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.